Skip to main content
NovaBay Pharmaceuticals, Inc. logo

NovaBay Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · NBY ISIN · US66987P2011 LEI · 549300D5U7PQPNEX8Q38 US Manufacturing
Open in API
Filings indexed 1,026 across all filing types
Latest filing 2024-11-22 Declaration of Voting R…
Country US United States of America
Listing US NBY

About NovaBay Pharmaceuticals, Inc.

https://novabay.com/

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes scientifically-created and clinically-proven products for the eyecare, skincare, and wound care markets. The company's core technology is a proprietary, stable formulation of hypochlorous acid. Its leading product is Avenova®, an antimicrobial lid and lash solution available over-the-counter for eye hygiene. In the wound care sector, NovaBay manufactures and sells products under the NeutroPhase® and PhaseOne® brands, which utilize its hypochlorous acid technology to aid in cleansing and debridement. The company focuses on providing accessible, problem-solving solutions for improved well-being.

Recent filings

Filing Released Lang Actions
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The content focuses on the submission of matters to a vote of security holders at a Special Meeting, including voting results and adjournment details. It also references a press release and the continuation of proxy solicitation. There are no financial statements or detailed financial data presented, nor is this a full annual or quarterly report. The primary content is the official results from shareholder votes and related meeting information. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and detail support this classification with high confidence.
2024-11-22 English
FORM DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a filing titled 'FORM DEFA14A' which is a Definitive Additional Materials filing related to a proxy statement. It discusses proxy proposals for the sale of assets and voluntary liquidation, urging stockholders to vote on these proposals. It references the Special Meeting Proxy Statement and supplements filed previously. The document is clearly related to proxy solicitation and shareholder voting materials, not a full annual report, earnings release, or other financial report. The presence of 'DEFA14A' in the header and the content about proxy proposals and solicitation confirms this is a Remuneration Information or Proxy Solicitation related filing. Given the detailed proxy solicitation content and the form type, the best classification is Proxy Solicitation & Information Statement (PSI).
2024-11-15 English
FORM DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a proxy solicitation communication related to a special meeting of stockholders, urging shareholders to vote before the meeting date. It is identified as a Schedule 14A filing, specifically marked as "Definitive Additional Materials" to a proxy statement. The content focuses on voting instructions and the importance of shareholder participation, without containing financial data, management discussion, or detailed report content. This matches the definition of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings. The document length is short and does not contain financial statements or detailed analysis, so it is not an Annual Report or Management Report. Therefore, the correct classification is PSI.
2024-11-13 English
FORM DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a definitive additional material supplement to a Proxy Statement filed on Schedule 14A with the SEC. It discusses proposals for a special meeting of stockholders, including an asset sale and company dissolution, and provides detailed information about voting procedures and amendments to the asset purchase agreement. The document is clearly a proxy solicitation material intended to inform and solicit votes from shareholders regarding corporate actions. It is not an annual report, earnings release, or other financial report, but rather a communication related to shareholder voting and corporate governance matters. Therefore, the appropriate classification is 'Proxy Solicitation & Information Statement' (PSI). The document length and content confirm it is not a brief announcement or a report publication announcement but a substantive proxy solicitation document.
2024-11-12 English
FORM DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a letter urging shareholders to vote in a special meeting scheduled for November 22, 2024. It references a proxy statement and voting instructions but does not contain the proxy statement itself or detailed meeting materials. The document is short (2672 characters) and serves as additional materials related to a proxy solicitation, specifically a reminder to vote. The SEC form referenced is DEFA14A, which is used for definitive additional proxy materials. This fits the category of Proxy Solicitation & Information Statement (PSI), as it is related to shareholder voting and proxy materials but is not the full proxy statement itself.
2024-11-12 English
NBY 13G/A
Major Shareholding Notification
2024-11-08 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.